File Download
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Article: EZH2 protein: A promising immunomarker for the detection of hepatocellular carcinomas in liver needle biopsies
  • Basic View
  • Metadata View
  • XML View
TitleEZH2 protein: A promising immunomarker for the detection of hepatocellular carcinomas in liver needle biopsies
 
AuthorsCai, MY2 2
Tong, ZT2
Zheng, F2
Liao, YJ2
Wang, Y2
Rao, HL2 2
Chen, YC3
Wu, QL2 2
Liu, YH1
Guan, XY2
Lin, MC2 3
Zeng, YX2
Kung, HF2 3
Xie, D2
 
Issue Date2011
 
PublisherBMJ Publishing Group. The Journal's web site is located at http://gut.bmjjournals.com/
 
CitationGut, 2011, v. 60 n. 7, p. 967-976 [How to Cite?]
DOI: http://dx.doi.org/10.1136/gut.2010.231993
 
AbstractBackground and aims: A previous study of ours indicated that enhancer of zeste homologue 2 (EZH2) plays an important role in hepatocellular carcinoma (HCC) tumorigenesis. The aim of the present study was to investigate the potential diagnostic utility of EZH2 in HCC. Methods: Immunohistochemistry was performed to examine the expression dynamics of EZH2 in two independent surgical cohorts of HCC and non-malignant liver tissues to develop a diagnostic yield of EZH2, HSP70 and GPC3 for HCC detection. The diagnostic performances of EZH2 and a three-marker panel in HCC were re-evaluated by using an additional biopsy cohort. Results: Immunohistochemistry analysis demonstrated that the sensitivity and specificity of EZH2 for HCC detection was 95.8% and 97.8% in the testing cohort. Similar results were confirmed in the validation cohort. For diagnosis of well-differentiated HCCs, the sensitivity and specificity were 68.9% and 91.5% for EZH2, 62.5% and 98.5% for HSP70, 50.0% and 92.1% for GPC3, and 75.0% and 100% for a three-marker panel. In biopsies, positive cases for at least one marker increased from large regenerative nodule and hepatocellular adenoma (0/12) to focal nodular hyperplasia (2/20), dysplastic nodule (7/25), well-differentiated HCC (16/18) and moderately and poorly differentiated HCC (54/54). When at least two positive markers were considered, regardless of their identity, the positive cases were detected in 0/12 large regenerative nodules and hepatocellular adenomas, 0/20 focal nodular hyperplasias, 0/25 dysplastic nodules, 11/18 well-differentiated HCCs, 32/37 moderately differentiated HCCs and 15/17 poorly differentiated HCCs. Conclusion: Our findings suggest that EZH2 protein, as examined by immunohistochemistry, may serve as a promising diagnostic biomarker of HCCs, and the use of a three-marker panel (EZH2, HSP70 and GPC3) can improve the rate of detection of HCCs in liver biopsy tissues.
 
ISSN0017-5749
2012 Impact Factor: 10.732
2012 SCImago Journal Rankings: 3.379
 
DOIhttp://dx.doi.org/10.1136/gut.2010.231993
 
ISI Accession Number IDWOS:000291306900016
Funding AgencyGrant Number
China's 973 National Basic Research Programme2010CB529401
2010CB912803
863 High Technology Development Programme2007AA021901
Guangzhou Science and Technology Bureau Foundation2005Z1-E0131
Funding Information:

This study was supported by grants made under China's 973 National Basic Research Programme (Nos. 2010CB529401 and 2010CB912803) and 863 High Technology Development Programme (No. 2007AA021901), and by a grant from the Guangzhou Science and Technology Bureau Foundation (No. 2005Z1-E0131).

 
ReferencesReferences in Scopus
 
DC FieldValue
dc.contributor.authorCai, MY
 
dc.contributor.authorTong, ZT
 
dc.contributor.authorZheng, F
 
dc.contributor.authorLiao, YJ
 
dc.contributor.authorWang, Y
 
dc.contributor.authorRao, HL
 
dc.contributor.authorChen, YC
 
dc.contributor.authorWu, QL
 
dc.contributor.authorLiu, YH
 
dc.contributor.authorGuan, XY
 
dc.contributor.authorLin, MC
 
dc.contributor.authorZeng, YX
 
dc.contributor.authorKung, HF
 
dc.contributor.authorXie, D
 
dc.date.accessioned2011-08-26T14:22:15Z
 
dc.date.available2011-08-26T14:22:15Z
 
dc.date.issued2011
 
dc.description.abstractBackground and aims: A previous study of ours indicated that enhancer of zeste homologue 2 (EZH2) plays an important role in hepatocellular carcinoma (HCC) tumorigenesis. The aim of the present study was to investigate the potential diagnostic utility of EZH2 in HCC. Methods: Immunohistochemistry was performed to examine the expression dynamics of EZH2 in two independent surgical cohorts of HCC and non-malignant liver tissues to develop a diagnostic yield of EZH2, HSP70 and GPC3 for HCC detection. The diagnostic performances of EZH2 and a three-marker panel in HCC were re-evaluated by using an additional biopsy cohort. Results: Immunohistochemistry analysis demonstrated that the sensitivity and specificity of EZH2 for HCC detection was 95.8% and 97.8% in the testing cohort. Similar results were confirmed in the validation cohort. For diagnosis of well-differentiated HCCs, the sensitivity and specificity were 68.9% and 91.5% for EZH2, 62.5% and 98.5% for HSP70, 50.0% and 92.1% for GPC3, and 75.0% and 100% for a three-marker panel. In biopsies, positive cases for at least one marker increased from large regenerative nodule and hepatocellular adenoma (0/12) to focal nodular hyperplasia (2/20), dysplastic nodule (7/25), well-differentiated HCC (16/18) and moderately and poorly differentiated HCC (54/54). When at least two positive markers were considered, regardless of their identity, the positive cases were detected in 0/12 large regenerative nodules and hepatocellular adenomas, 0/20 focal nodular hyperplasias, 0/25 dysplastic nodules, 11/18 well-differentiated HCCs, 32/37 moderately differentiated HCCs and 15/17 poorly differentiated HCCs. Conclusion: Our findings suggest that EZH2 protein, as examined by immunohistochemistry, may serve as a promising diagnostic biomarker of HCCs, and the use of a three-marker panel (EZH2, HSP70 and GPC3) can improve the rate of detection of HCCs in liver biopsy tissues.
 
dc.description.naturepublished_or_final_version
 
dc.identifier.citationGut, 2011, v. 60 n. 7, p. 967-976 [How to Cite?]
DOI: http://dx.doi.org/10.1136/gut.2010.231993
 
dc.identifier.doihttp://dx.doi.org/10.1136/gut.2010.231993
 
dc.identifier.epage976
 
dc.identifier.hkuros190887
 
dc.identifier.isiWOS:000291306900016
Funding AgencyGrant Number
China's 973 National Basic Research Programme2010CB529401
2010CB912803
863 High Technology Development Programme2007AA021901
Guangzhou Science and Technology Bureau Foundation2005Z1-E0131
Funding Information:

This study was supported by grants made under China's 973 National Basic Research Programme (Nos. 2010CB529401 and 2010CB912803) and 863 High Technology Development Programme (No. 2007AA021901), and by a grant from the Guangzhou Science and Technology Bureau Foundation (No. 2005Z1-E0131).

 
dc.identifier.issn0017-5749
2012 Impact Factor: 10.732
2012 SCImago Journal Rankings: 3.379
 
dc.identifier.issue7
 
dc.identifier.pmid21330577
 
dc.identifier.scopuseid_2-s2.0-79958219307
 
dc.identifier.spage967
 
dc.identifier.urihttp://hdl.handle.net/10722/137272
 
dc.identifier.volume60
 
dc.languageeng
 
dc.publisherBMJ Publishing Group. The Journal's web site is located at http://gut.bmjjournals.com/
 
dc.publisher.placeUnited Kingdom
 
dc.relation.ispartofGut
 
dc.relation.referencesReferences in Scopus
 
dc.rightsGut. Copyright © BMJ Publishing Group.
 
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License
 
dc.subject.meshCarcinoma, Hepatocellular - diagnosis - pathology
 
dc.subject.meshDNA-Binding Proteins - metabolism
 
dc.subject.meshLiver Neoplasms - diagnosis - pathology
 
dc.subject.meshTranscription Factors - metabolism
 
dc.subject.meshTumor Markers, Biological - metabolism
 
dc.titleEZH2 protein: A promising immunomarker for the detection of hepatocellular carcinomas in liver needle biopsies
 
dc.typeArticle
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Cai, MY</contributor.author>
<contributor.author>Tong, ZT</contributor.author>
<contributor.author>Zheng, F</contributor.author>
<contributor.author>Liao, YJ</contributor.author>
<contributor.author>Wang, Y</contributor.author>
<contributor.author>Rao, HL</contributor.author>
<contributor.author>Chen, YC</contributor.author>
<contributor.author>Wu, QL</contributor.author>
<contributor.author>Liu, YH</contributor.author>
<contributor.author>Guan, XY</contributor.author>
<contributor.author>Lin, MC</contributor.author>
<contributor.author>Zeng, YX</contributor.author>
<contributor.author>Kung, HF</contributor.author>
<contributor.author>Xie, D</contributor.author>
<date.accessioned>2011-08-26T14:22:15Z</date.accessioned>
<date.available>2011-08-26T14:22:15Z</date.available>
<date.issued>2011</date.issued>
<identifier.citation>Gut, 2011, v. 60 n. 7, p. 967-976</identifier.citation>
<identifier.issn>0017-5749</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/137272</identifier.uri>
<description.abstract>Background and aims: A previous study of ours indicated that enhancer of zeste homologue 2 (EZH2) plays an important role in hepatocellular carcinoma (HCC) tumorigenesis. The aim of the present study was to investigate the potential diagnostic utility of EZH2 in HCC. Methods: Immunohistochemistry was performed to examine the expression dynamics of EZH2 in two independent surgical cohorts of HCC and non-malignant liver tissues to develop a diagnostic yield of EZH2, HSP70 and GPC3 for HCC detection. The diagnostic performances of EZH2 and a three-marker panel in HCC were re-evaluated by using an additional biopsy cohort. Results: Immunohistochemistry analysis demonstrated that the sensitivity and specificity of EZH2 for HCC detection was 95.8% and 97.8% in the testing cohort. Similar results were confirmed in the validation cohort. For diagnosis of well-differentiated HCCs, the sensitivity and specificity were 68.9% and 91.5% for EZH2, 62.5% and 98.5% for HSP70, 50.0% and 92.1% for GPC3, and 75.0% and 100% for a three-marker panel. In biopsies, positive cases for at least one marker increased from large regenerative nodule and hepatocellular adenoma (0/12) to focal nodular hyperplasia (2/20), dysplastic nodule (7/25), well-differentiated HCC (16/18) and moderately and poorly differentiated HCC (54/54). When at least two positive markers were considered, regardless of their identity, the positive cases were detected in 0/12 large regenerative nodules and hepatocellular adenomas, 0/20 focal nodular hyperplasias, 0/25 dysplastic nodules, 11/18 well-differentiated HCCs, 32/37 moderately differentiated HCCs and 15/17 poorly differentiated HCCs. Conclusion: Our findings suggest that EZH2 protein, as examined by immunohistochemistry, may serve as a promising diagnostic biomarker of HCCs, and the use of a three-marker panel (EZH2, HSP70 and GPC3) can improve the rate of detection of HCCs in liver biopsy tissues.</description.abstract>
<language>eng</language>
<publisher>BMJ Publishing Group. The Journal&apos;s web site is located at http://gut.bmjjournals.com/</publisher>
<relation.ispartof>Gut</relation.ispartof>
<rights>Gut. Copyright &#169; BMJ Publishing Group.</rights>
<rights>Creative Commons: Attribution 3.0 Hong Kong License</rights>
<subject.mesh>Carcinoma, Hepatocellular - diagnosis - pathology</subject.mesh>
<subject.mesh>DNA-Binding Proteins - metabolism</subject.mesh>
<subject.mesh>Liver Neoplasms - diagnosis - pathology</subject.mesh>
<subject.mesh>Transcription Factors - metabolism</subject.mesh>
<subject.mesh>Tumor Markers, Biological - metabolism</subject.mesh>
<title>EZH2 protein: A promising immunomarker for the detection of hepatocellular carcinomas in liver needle biopsies</title>
<type>Article</type>
<description.nature>published_or_final_version</description.nature>
<identifier.doi>10.1136/gut.2010.231993</identifier.doi>
<identifier.pmid>21330577</identifier.pmid>
<identifier.scopus>eid_2-s2.0-79958219307</identifier.scopus>
<identifier.hkuros>190887</identifier.hkuros>
<relation.references>http://www.scopus.com/mlt/select.url?eid=2-s2.0-79958219307&amp;selection=ref&amp;src=s&amp;origin=recordpage</relation.references>
<identifier.volume>60</identifier.volume>
<identifier.issue>7</identifier.issue>
<identifier.spage>967</identifier.spage>
<identifier.epage>976</identifier.epage>
<identifier.isi>WOS:000291306900016</identifier.isi>
<publisher.place>United Kingdom</publisher.place>
<bitstream.url>http://hub.hku.hk/bitstream/10722/137272/1/content.pdf</bitstream.url>
</item>
Author Affiliations
  1. Guangdong Provincial People's Hospital
  2. Sun Yat-Sen University
  3. Chinese University of Hong Kong